Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Ramiroet al
Author:
Publisher
BMJ
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference9 articles.
1. Braun J . Correspondence on “ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update” by Ramiro et al. Ann Rheum Dis 2023. doi:10.1136/ard-2023-223935
2. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
3. Brief report: six-week treatment of axial spondyloarthritis patients with an optimal dose of nonsteroidal antiinflammatory drugs: early response to treatment in signal intensity on magnetic resonance imaging of the sacroiliac joints;Varkas;Arthritis Rheumatol,2016
4. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
5. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study;Rheumatology Science and Practice;2023-12-31
2. Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA;Modern Rheumatology Journal;2023-12-19
3. Diffuse idiopathic skeletal hyperostosis and axial spondyloarthritis—similarities and differences;Exploration of Musculoskeletal Diseases;2023-11-20
4. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis;Rheumatology;2023-11-08
5. Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy;Rheumatology Science and Practice;2023-10-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3